Wall Street's Next Biotech Winners Emerge as FDA Acceleration Unleashes New Markets [TheStreet.com]
NeoGenomics, Inc. (NEO)
Last neogenomics, inc. earnings: 4/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.neogenomics.com
Company Research
Source: TheStreet.com
Denver, Colorado ( 247marketnews.com ) - The biotech and health-tech landscape is entering a new acceleration phase, driven by regulatory momentum, AI integration, and a surge in precision medicine. Companies like NeoGenomics (NASDAQ:NEO) are capitalizing on this shift with tangible operating performance. The company reported first-quarter 2026 revenue of $187 million, up 11% year-over-year, fueled by 14% clinical growth and a striking 26% expansion in next-generation sequencing (NGS). More importantly, NeoGenomics is positioning itself in the rapidly expanding minimal residual disease (MRD) market, estimated at $20 billion and growing at roughly 30% annually, still largely underpenetrated. That growth narrative is reinforced by product innovation and reimbursement wins. The launch of RaDaR ST and favorable MolDX coverage for PanTracer LBx signal increasing clinical adoption and payer validation, two critical levers for scaling diagnostics businesses. With adjusted EBITDA turning
Show less
Read more
Impact Snapshot
Event Time:
NEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NEO alerts
High impacting NeoGenomics, Inc. news events
Weekly update
A roundup of the hottest topics
NEO
News
- NeoGenomics (NEO) was upgraded by Leerink Partners from "market perform" to "outperform". They now have a $25.00 price target on the stock.MarketBeat
- NeoGenomics (NEO) was upgraded by Benchmark Co. from "hold" to "buy".MarketBeat
- NeoGenomics (NEO) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- NeoGenomics (NEO) Q1 2026 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- NeoGenomics's (NASDAQ:NEO) Q1 CY2026: Beats On Revenue [Yahoo! Finance]Yahoo! Finance
NEO
Earnings
- 4/28/26 - Beat
NEO
Sec Filings
- 4/28/26 - Form 10-Q
- 4/28/26 - Form 8-K
- 4/6/26 - Form DEFA14A
- NEO's page on the SEC website